Peptide Library

FDA-approved

Heart & blood

Pegcetacoplan

Evidence

FDA approved

Class

Complement C3 inhibitor peptide

/

Pegcetacoplan

KEY TAKEAWAY

Pegcetacoplan is a cyclic peptide that blocks complement protein C3, attached to polyethylene glycol to last longer. It is sold as Empaveli and, for the eye, as Syfovre. The FDA approved pegcetacoplan (Empaveli) in 2021 for paroxysmal nocturnal hemoglobinuria and (Syfovre) in 2023 for geographic atrophy, with later approvals for some kidney diseases.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Complement C3 inhibitor peptide

Approved for

Paroxysmal nocturnal hemoglobinuria, certain kidney diseases and geographic atrophy of the eye

Key fact

The FDA approved pegcetacoplan (Empaveli) in 2021 for paroxysmal nocturnal hemoglobinuria and (Syfovre) in 2023 for geographic atrophy, with later approvals for some kidney diseases.

Route

Subcutaneous infusion, or injection into the eye

Evidence strength

FDA approved

What it is

What it is

Pegcetacoplan is a cyclic peptide that blocks complement protein C3, attached to polyethylene glycol to last longer. It is sold as Empaveli and, for the eye, as Syfovre.

How it works

How it works

It stops the complement system from destroying red blood cells and from damaging cells in the retina.

Regulatory status

Regulatory status

The FDA approved pegcetacoplan (Empaveli) in 2021 for paroxysmal nocturnal hemoglobinuria and (Syfovre) in 2023 for geographic atrophy, with later approvals for some kidney diseases.

What it is used for

What it is used for

Paroxysmal nocturnal hemoglobinuria, certain kidney diseases and geographic atrophy of the eye.

Side effects and risks

Side effects and risks

The injected form carries a boxed warning for serious infections with encapsulated bacteria. The eye injection can cause inflammation and wet macular degeneration.

Citations

Citations

U.S. FDA prescribing information for Pegcetacoplan. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo